Hello, everyone, and welcome to the middle of the week. You made it this far, so why not acknowledge the moment with a non-carcinogenic cup of stimulation? After all, consider the alternatives. Before we continue, we would like to note that we will take an extended break to attend to a milestone for the shortest of our short people. We will return next week. Meanwhile, we hope you have a productive couple of days and a delightful weekend. And now, here are some tidbits. Stay well, y’all …
The American Diabetes Association let hundreds, possibly thousands, of attendees see new study data on Novo Nordisk’s Victoza diabetes drugs more than an hour before its official release to the public and the markets, Bloomberg News says. The attendees were asked not to tweet the info, but — surprise! — some folks tweeted pictures of charts within minutes.
Federal incentives to drug makers have helped lead to at least seven late-stage antibiotics that may fight bacteria that can become dangerous superbugs, the Wall Street Journal writes. “We have built a robust portfolio of broad-spectrum antibiotics that possess activity” against the microbes, Richard Hatchett, acting director of the government’s Biomedical Advanced Research and Development Authority, told lawmakers.
Valeant Pharmaceuticals’s new chief executive, Joe Papa, told shareholders Tuesday that the beleaguered drug maker is looking to sell assets to reduce its $30 billion in debt, including the Bausch & Lomb eye care subsidiary, Fox Business tells us. And the move may put him at odds with Valeant’s largest shareholder, activist investor William Ackman.
Patient advocacy groups, including Doctors Without Borders, are objecting to proposals made during talks for the Regional Comprehensive Economic Partnership trade deal, PharmaBiz reports. They want negotiators to remove what they call alarming intellectual property proposals that would go beyond what are required by international trade, because the suggestions would undermine access to affordable generic medicines.
A new analysis of common medicines for diabetes, high blood pressure, and depression found that at least 1 in 10 patients received a treatment course of drugs that no other patient with the same condition did, Quartz reports. In other words, more than 25 million people were essentially treated by guesswork. The study appeared in the Proceedings of the National Academy of Sciences.
The Rwandan government; Gavi, the Vaccine Alliance; and and a small Silicon Valley startup called Zipline are testing the use of drones to deliver medicines, writes Pharmaceutical Commerce.
Hospitals are struggling with fast-rising drugs prices, because they are capped at how much they can charge payers like Medicare and Medicaid, Modern Healthcare reports.
Eli Lilly’s Jardiance diabetes drug cut the risk of progressive kidney disease in adults with type 2 diabetes in a study that had already shown the medicine lowers cardiovascular deaths, Reuters tells us.